Lazard Capital Initiates Coverage on Epocrates (EPOC)

By admin | 6 years ago

Research analysts at Lazard Capital began coverage on shares of Epocrates (NASDAQ: EPOC) in a report released on Wednesday. The firm set a “sell” rating on the stock.

Shares of Epocrates traded up 0.50% during mid-day trading on Wednesday, hitting $8.04. Epocrates has a 52 week low of $7.20 and a 52 week high of $23.71. The company’s market cap is $198.1 million.

EPOC has been the subject of a number of other recent research reports. Analysts at Raymond James (NYSE: RJF) upgraded shares of Epocrates from an “underperform” rating to a “market perform” rating in a research note to investors on Friday, March 9th. Analysts at Piper Jaffray (NYSE: PJC) raised their price target on shares of Epocrates to $13.00 in a research note to investors on Wednesday, February 29th.

Epocrates, Inc. is a provider of clinical information and decision support tools to healthcare professionals, as well as interactive information services to the healthcare industry.

About the author